

**FOR IMMEDIATE RELEASE**



**Quantonation Announces Novo Holdings' Investment in Quantum Venture Fund Quantonation II to Strengthen Global Quantum Ecosystem Collaboration and Advance Quantum Solutions**

Paris, France and Boston, USA – January 27<sup>th</sup>, 2025

Quantonation Ventures, the leading quantum technology investment fund with a global reach, is proud to announce a strategic investment from Novo Holdings in Quantonation II. This investment underscores Novo Holdings' commitment to fostering innovation and addressing critical global challenges through advancements in science and technology. By focusing on sectors such as precision medicine, new materials, and climate change mitigation, this partnership is set to unlock new opportunities for quantum startups, driving meaningful change and transformative solutions. This investment in Quantonation II aims to accelerate the development of quantum technologies that can have transformative social and environmental impact on applications in the healthcare industry, particularly in the Nordics.

Established in 2018, Quantonation is the world's largest venture capital fund specializing in quantum technology. It invests globally and has already deployed its first fund, Quantonation I, with AUM totaling €91 million, invested across 27 startup companies, including investments in Pasqal, a global leader in neutral atoms quantum computing, Qubit Pharmaceuticals, a quantum-aided drug discovery company, and quantum AI leader Multiverse Computing.

Quantonation is now raising and deploying its Fund II, with €112 million already raised and a €200 million target by the end of Q2 2025. Quantonation II has already invested more than €30 million in groundbreaking companies such as Diraq, Resolve Stroke, Steerlight, QBlox, Pioniq, Quantum Signals, and Tau Systems across the globe.

Novo Holdings' investment in Quantonation II aligns with its mission to back groundbreaking technologies that address societal, environmental and healthcare-related challenges. The investment from Novo Holdings marks the launch of its investment program in quantum technologies.

Christophe Jurczak, Managing Partner of Quantonation, stated: "We are honored to welcome Novo Holdings as a strategic partner. Their vision and commitment to creating lasting social and environmental impact align perfectly with Quantonation's mission to drive the quantum revolution. Together, we aim to empower startups in our portfolio to transform quantum innovations into tangible solutions that benefit humanity."

The collaboration between Quantonation and Novo Holdings highlights the growing recognition of quantum technology as a pivotal tool in addressing global challenges.

---

### **About Novo Holdings**

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.

[www.novoholdings.dk](http://www.novoholdings.dk)

**About Quantonation:**

Quantonation is the first early-stage VC fund dedicated to deep physics and quantum technologies. Fields such as high-performance computation, secure communications, drug design, or ultra-precise sensing are now driven by innovation based on these disruptive technologies. Quantonation aims at supporting their transition into commercially available products. Quantonation is headquartered in Paris, France, and in Boston, USA, with investments in Europe, North America, and Asia-Pacific. More on [www.quantonation.com](http://www.quantonation.com) or LinkedIn (<https://fr.linkedin.com/company/quantonation>).

**Quantonation contact:** Eléonore de Rose, Director of communications and PR  
- [eleonore@quantonation.com](mailto:eleonore@quantonation.com) - +33 6 62 64 40 53